Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS).  The SPA agreement with the FDA validates the cl ...

Core Viewpoint - BrainStorm Cell Therapeutics Inc. is set to provide an update on its NurOwn® program during a conference call scheduled for April 9, 2024, at 8:00 AM Eastern Time, aimed at informing shareholders and the investment community about recent developments [1]. Group 1: Company Overview - BrainStorm Cell Therapeutics Inc. specializes in developing innovative autologous adult stem cell therapies for neurodegenerative diseases [2]. - The company holds exclusive rights to the NurOwn® technology platform, which produces autologous MSC-NTF cells, and has received Orphan Drug designation from both the U.S. FDA and the European Medicines Agency for treating amyotrophic lateral sclerosis (ALS) [2]. - BrainStorm has completed a Phase 3 pivotal trial for ALS, which investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells, supported by a grant from the California Institute for Regenerative Medicine [2]. Group 2: Upcoming Events - The conference call will feature presentations from key executives, including the President and CEO, Co-CEO, and Chief Development Officer, followed by a Q&A session with the investment community [1]. - Participants can join the call via a provided link or by dialing specific toll-free and international numbers [1]. Group 3: Additional Information - A replay of the conference call will be available until April 24, 2024, allowing interested parties to listen to the discussion at a later time [1][2].

Table of Contents IdentificationNo.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ COMMISSION FILE NUMBER 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact Name of Registrant as specified in its charter) Delaw ...

Exhibit 99.1 BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update Conference call planned for early April 2024 to provide update on NurOwn program NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update. "Brainstorm's priority for 2024 i ...

Conference call planned for early April 2024 to provide update on NurOwn program NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update. "Brainstorm's priority for 2024 is to move forward with a confirmatory Phase 3b trial for NurOwn that will potentially support a new Biologics Licen ...

NEW YORK, Feb. 23, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) for a Phase 3b study of NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS). The submission follows an in-person meeting that BrainStorm held with the FDA in December 2023. The inter ...

NEW YORK, Feb. 13, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will provide a corporate update at the 17th Annual European Life Sciences CEO Forum to take place 28 - 29 of February, 2024 in Zurich, Switzerland. Presentation DetailsPresentation Date: Wednesday, 28th FebruaryTime: 13:40h CETLocation: Panorama Room (Track C), Hilton Zurich Airport Hotel Dr. Stacy Lindborg, Co-C ...

Start Time: 08:30 January 1, 0000 8:58 AM ET BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Chaim Lebovits - President and CEO Stacy Lindborg - Co-CEO Alla Patlis - Interim CFO Michael Wood - LifeSci Advisors Conference Call Participants David Bautz - Zacks Small-Cap Research Operator Greetings, and welcome to the BrainStorm Cell Therapeutics Third Quarter 2023 Earnings Call. At this time, participants are in a listen-only ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specifie ...

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Michael Wood - LifeSci Advisors Chaim Lebovits - President and Chief Executive Officer Stacy Lindborg - Co-Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Kirk Taylor - Executive Vice President and Chief Medical Officer Conference Call Participants Jason McCarthy - Maxim Group Operator Greetings, and welcome to the Brainstorm Cell Therapeutics Second Quarter ...